News
Phenomenex Introduces Biozen™ Native RP-1 and RP-5: A Novel Way to Characterize ADCs with Unmatched Throughput and High-Quality Data Published 9:01 am Tuesday, March 25, 2025 ...
Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials ...
Initial TRESR data provide clinical proof of concept and validate Repare Therapeutics' SNIPRx platform for molecular selection of tumors for therapy with RP-3500 Favorable and differentiated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback